{
    "clinical_study": {
        "@rank": "35315", 
        "acronym": "RECOVERII", 
        "arm_group": [
            {
                "arm_group_label": "Prourokinase", 
                "arm_group_type": "Experimental", 
                "description": "Intracoronary bolus infusion of 20mg prourokinase using selective catheter"
            }, 
            {
                "arm_group_label": "Tirofiban", 
                "arm_group_type": "Active Comparator", 
                "description": "Intracoronary bolus infusion using selective catheter (10ug/kg)"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine whether intracoronary selective thrombolysis are\n      more effective than tirofiban on the coronary flow during primary  percutaneous coronary\n      intervention for the acute myocardial infarction."
        }, 
        "brief_title": "Effects of Intracoronary Prourokinase on the Coronary Flow During Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Myocardial Infarction", 
            "Percutaneous Coronary Intervention", 
            "Thrombolytic Therapy"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Infarction", 
                "Myocardial Infarction"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  ST-segment elevation AMI within 12 hours of symptom onset\n\n        Exclusion Criteria:\n\n          -  Contraindications to thrombolysis or PCI\n\n          -  Patients administered a fibrinolytic agent before PCI\n\n          -  Patients enrolled in clinical trials"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "200", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 3, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02131220", 
            "org_study_id": "Zhongshan 2012-134"
        }, 
        "intervention": [
            {
                "arm_group_label": "Prourokinase", 
                "description": "20mg intracoronary bolus infusion using selective catheter during PCI", 
                "intervention_name": "Prourokinase", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Reocmbinant Human Prourokinase for Injection", 
                    "TIANJIN TASLY PHARMACEUTICAL CO.,LTD"
                ]
            }, 
            {
                "arm_group_label": "Tirofiban", 
                "description": "10ug/kg intracoronary bolus infusion using selective catheter during PCI", 
                "intervention_name": "Tirofiban", 
                "intervention_type": "Drug", 
                "other_name": "Grand Pharmr (China) Co. Ltd"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Saruplase", 
                "Tirofiban"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": "No-Reflow Phenomenon", 
        "lastchanged_date": "May 3, 2014", 
        "location": {
            "contact": {
                "email": "huang.dong@zs-hospital.sh.cn", 
                "last_name": "Dong Huang, M.D.", 
                "phone": "862113512142875"
            }, 
            "facility": {
                "address": {
                    "city": "Shanghai", 
                    "country": "China", 
                    "state": "Shanghai", 
                    "zip": "200032"
                }, 
                "name": "Department of Cardiology, Zhongshan Hospital, Fudan University"
            }, 
            "investigator": {
                "last_name": "Dong Huang, M.D.", 
                "role": "Sub-Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "Effects of Intracoronary Prourokinase or Tirofiban on the Coronary Flow During Primary Percutaneous Coronary Intervention for the Acute Myocardial Infarction", 
        "other_outcome": {
            "measure": "TIMI defined total major bleeding", 
            "safety_issue": "Yes", 
            "time_frame": "30 days post PCI"
        }, 
        "overall_contact": {
            "email": "huang.dong@zs-hospital.sh.cn", 
            "last_name": "Dong Huang, M.D.", 
            "phone": "862113512142875"
        }, 
        "overall_official": {
            "affiliation": "Department of Cardiology, Zhongshan Hospital, Fudan University", 
            "last_name": "Junbo Ge, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Coronary flow using corrected Thrombolysis In Myocardial Infarction Frame Count (cTFC)", 
            "safety_issue": "No", 
            "time_frame": "At the end of Percutaneous Coronary Intervention procedure"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02131220"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Fudan University", 
            "investigator_full_name": "Ge Junbo", 
            "investigator_title": "Director, Dept. of Cardiology, Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "ST segment resolution in ECG", 
                "safety_issue": "No", 
                "time_frame": "3 hours post PCI procedure"
            }, 
            {
                "measure": "peak troponin T level", 
                "safety_issue": "No", 
                "time_frame": "in the 7 days post PCI procedure"
            }, 
            {
                "measure": "plasma N terminal-proBNP levels", 
                "safety_issue": "No", 
                "time_frame": "1 and 30 days post PCI procedure"
            }, 
            {
                "measure": "infarction area confirmed by SPECT", 
                "safety_issue": "No", 
                "time_frame": "30 days post PCI"
            }, 
            {
                "measure": "incidence of major adverse cardiac events (MACE) defined as the composite of death, myocardial infarction and target vessel revascularization", 
                "safety_issue": "No", 
                "time_frame": "30 days post PCI"
            }
        ], 
        "source": "Fudan University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Fudan University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}